
To review the zzso zzso clinical zzso adverse events, zzso and administration of zzso zzso spray in the treatment of breakthrough cancer pain zzso in zzso 

zzso published data were identified using zzso from inception to April 2012 using the search terms zzso zzso spray, zzso zzso zzso zzso cancer pain, and zzso zzso cancer zzso Only articles evaluating the use of zzso zzso spray for cancer pain were zzso 

All articles evaluating the zzso of zzso zzso or the clinical efficacy of zzso zzso spray for the treatment of zzso were zzso references of selected articles were manually reviewed to identify further zzso The manufacturer of zzso zzso spray was also contacted to obtain zzso 

zzso zzso spray gained Food and Drug Administration approval for the treatment of zzso in adults with cancer receiving stable background zzso therapy for chronic zzso In doses ranging from 100 to 800 zzso zzso zzso spray was found to be more effective than zzso and more effective than oral zzso or oral zzso zzso in reducing pain for up to zzso minutes; onset of analgesia was also improved with zzso zzso zzso The most commonly observed adverse events included zzso zzso zzso and zzso 

For the treatment of zzso zzso zzso spray offers improved onset of analgesia compared to other oral zzso this improved onset of analgesia may closely mimic the typical time course of a zzso zzso zzso administration may overcome problems such as zzso zzso or zzso that may complicate oral administration of zzso Potential disadvantages include uncertainty in treating more than 4 zzso episodes per 24 hours and a higher cost compared to generically available oral zzso zzso 

